Equity in breast cancer care among breast cancer patients in Indonesia

<u>Ardhina Nugrahaeni</u>, Nopryan Ekadinata Center for Health Policy and Management, Gadjah Mada University, Indonesia

Introduction


- Breast cancer is a leading death cause in Indonesia.
- The number of new cases of breast cancer reached 68,858 cases (16.6%) of a total of 396,914 new cases of cancer in Indonesia^[1].
- Access to healthcare services (early detection facilities, pathology services, and essential medicine) and national health system strategy were crucial factors ^[2,3].



BPJS Kesehatan

- A quantitative observational study
- BPJS K represented approximately 1% of the BPJS data registry
- International Classification of Diseases (ICD) 10 code of C.50 was used as a primary diagnosis.
- Analyzing data used STATA software

Results



Discussion and Conclusion

Our findings highlighted the disparities in healthcare visits to breast cancer, especially in Indonesia's Region 5 which is less developed area and eastern region. Failure to prioritize this issue will perpetuate inequitable access to healthcare for breast cancer patients, leaving the problem unresolved. The main problem in the uneven distribution of breast cancer services in each region is due to access to health facilities, cancer teams, and the availability of health facilities. In conclusion, access to breast cancer services is inequitable, particularly in Eastern Indonesia

Acknowledgement

The authors would like to thank for Social Health Insurance Administration Body (BPJS-K) to provide BPJS-K sample data and Gadjah Mada University

References

2. De Souza, J. A., Hunt, B., Asirwa, F. C., Adebamowo, C., & Lopes, G. (2016). Global health equity: cancer care outcome disparities in high-, middle-, and low-income countries. Journal of Clinical Oncology, 34(1), 6.

3. Farmer, P., Frenk, J., Knaul, F. M., Shulman, L. N., Alleyne, G., Armstrong, L., ... & Seffrin, J. R. (2010). Expansion of cancer care and control in countries of low and middle income: a call to action. The Lancet, 376(9747), 1186-1193

^{1.} Globocan. International Agency for Research on Cancer. Indonesia. 2020